TrialJournal of clinical immunology2015

Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial.

Gadi Lalazar et al.PubMed ↗Publisher ↗

No numbers read from the abstract.